Background and objective Patients with early chronic kidney disease (CKD) face challenges in accessing healthcare, including delays in diagnosis, fragmented speciality care and lack of tailored education and psychosocial support. Patient navigator programmes have the potential to improve the process of care and outcomes. The objective of this study is to describe the experiences of patients on communication, access of care and self-management and their perspectives on patient navigator programmes in early CKD.
Design, setting and participants We convened a workshop in Australia with 19 patients with CKD (all stages including CKD Stage 1 to 5 not on dialysis, 5D (dialysis), and 5T (transplant)) and five caregivers. All of them were over 18 years and English-speaking. Transcripts from the workshop were analysed thematically.
Results Four themes that captured discussions were: lost in the ambiguity of symptoms and management, battling roadblocks while accessing care, emotionally isolated after diagnosis and re-establishing lifestyle and forward planning. Five themes that focussed on patient navigator programmes were: trust and credibility, respecting patient choices and readiness to accept the programme, using accessible language to promote the programme, offering multiple ways to engage and communicate and maintaining confidentiality and privacy. Of the 17 features identified as important for a patient navigator programme, the top five were delivery of education, psychosocial support, lifestyle modification, communication and decision-making support and facilitating care.
Conclusion Patient navigator services can address gaps in services around health literacy, communication, psychosocial support and coordination across multiple healthcare settings. In comparison to the existing navigator programmes, and other services that are aimed at addressing these gaps, credible, accessible and flexible patient navigator programmes for patients with early CKD, that support education, decision-making, access to care and self-management designed in partnership with patients, may be more acceptable to patients.
- QUALITATIVE RESEARCH
- Chronic renal failure
- Quality in health care
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
Strengths and limitations of this study
We elicited a range of patient and caregiver perspectives on self-management and access to care.
We included patients across the spectrum of chronic kidney disease to capture a broader range of perspectives.
The participants were all English-speaking and from Australia.
Guidelines on the management of early chronic kidney disease (CKD) recommend pharmacological, lifestyle and psychosocial interventions to minimise the risk of complications and disease progression.1 2 This requires a collaborative and multidisciplinary approach.3 However, patients with early CKD face substantial barriers in accessing and coordinating appropriate healthcare. Healthcare delivery is often fragmented into speciality silos and resources are predominantly invested in treatment rather than prevention. Other challenges include delays in the diagnosis of CKD and referral to nephrologists, poor follow-up, a lack of psychosocial support and education and difficulties navigating the complex treatment plans.4 5 This is particularly problematic in early CKD because patients can be asymptomatic with an uncertain prognosis.6 Barriers to follow-up after diagnosis may include costs, difficulties with travelling to clinic for testing and fear and confusion about laboratory results.5 There is also a lack of awareness of CKD among patients and the general public.7–9 These reasons may explain, to some extent, why access to education and multidisciplinary care to prevent the progression of CKD has been consistently identified as the top research priority among patients with early CKD.8 10 11
Patient navigator programmes have the potential to improve the process of care and outcomes and are increasingly implemented in the context of chronic disease, particularly for patients with cancer12 and diabetes.13 14 Patient navigator programmes facilitate access and manage care through education, care coordination and advocacy to reduce health disparities.15 16 Patient navigators are trained non-medical personnel (who may be patients, or other members from community, including individuals with a background in a health-related discipline) who assist patients with complex and/or chronic conditions journey through the continuum of care and transit across different care settings.12 17 They help underserved populations with chronic illness to better understand their diagnoses, treatment options and available resources, assist with navigating complex medical systems, overcoming barriers to healthcare access and bridging gaps in transitions of care.18
In the context of cancer, patient navigator programmes have improved patients’ satisfaction with care and treatment adherence.19–21 The navigators in these programmes have included healthcare professionals (eg, nurses and community workers) and respected individuals including community leaders (including cancer survivors). Navigators involved in such programmes needed to have an understanding of the range of services available, an ability to communicate with professionals and assist with obtaining or coordinating referrals to services.22 23
Patient navigator programmes for cancer and diabetes patients may not directly apply to patients with early CKD. The difference in disease symptoms, manifestations and treatments between these diseases (cancer and diabetes) and CKD lead us to question the transferability of the navigator programmes. Additionally, the evidence for patient navigator programmes for patients with early CKD remains uncertain and the ability to precisely outline successful components in patient navigator programmes across all chronic diseases remains limited.16 20 24 25 Studies show that patients are rarely involved in the design of patient navigator programmes meaning they may not address the priorities of patients and their carers.15
Context and scope
We conducted a workshop to discuss patient perspectives on access to care and self-management, to ascertain their perspectives on a patient navigator programme that can address barriers and challenges they may have encountered, to identify and prioritise features of such a patient navigator programme in early CKD (all stages of CKD before the need for kidney replacement therapy) and to discuss the acceptability and feasibility of implementation. In the workshop we also included patients on dialysis and kidney transplant recipients, who were able to reflect on their experiences prior to the need for kidney replacement therapy, and thus could provide relevant perspectives. The intent of the workshop was to inform a trial of a patient navigator programme for patients with early CKD (PAVE-CKD). The half-day workshop was conducted in a hotel meeting room in Sydney in May 2019.
Attendees and contributors
In total, 19 adult patients aged 18 years and over with CKD (not on kidney replacement therapy n=11, receiving dialysis n=6, kidney transplant recipients n=2) and five caregivers (family members) attended the workshop. The participants were from three cities (Sydney, Adelaide and Armidale) in Australia. The characteristics of the participants are provided in table 1. Invitations were sent to patients and caregivers by email through the Better Evidence and Translation in Chronic Kidney Diseases (BEAT-CKD) network. The full list of the PAVE-CKD workshop attendees and contributors is provided in the Acknowledgements.
Workshop programme and materials
The workshop programme outline and facilitator guide are provided in the online supplemental file 1 (Item S1 and Item S2, respectively). Participants received a printed copy of the project aims and a list of potential features (eg, facilitating care, delivery of education) of the navigator programme (Item S3 in the online supplemental file 1). The workshop had three phases: introduction, breakout discussions and plenary discussion.
Participants were pre-assigned to one of four facilitated breakout discussion groups of six to seven participants. To encourage an exchange of diverse perspectives, each group included a mix of caregivers and patients with early CKD, patients on dialysis and transplant recipients. Each group had one trained facilitator (PL-V, AT, AB and TG) and a co-facilitator (AJ, CG, NJS-R and RK). To guide the discussions, all facilitators used a standardised run sheet (Item S2 in the online supplemental file 1). The questions were developed based on a literature review on patient navigator programmes16 26 and discussion among the investigator team, which included multidisciplinary clinicians, patients and researchers.
During the first session participants discussed their experiences and perspectives of self-management, communication and education and access to care in CKD prior to the need for kidney replacement therapy.
In the second session, the concept of a navigator was explained, and participants in each group were given a copy of the list of 11 features of the navigator programme (Item S3 in the online supplemental file 1), identified from systematic reviews of patient navigator programmes.16 26 The role of the navigator was outlined against each feature. Participants were asked to review the 11 features of the navigator programme, add additional features to the list if required and explain the reasons for additional features and discuss how each feature of the programme might relate to their challenges identified during the first session. They were provided with three sticker dots of different colours to vote for the top three features that they thought were most important. The green sticker dot indicated rank ‘1’ (most important) and was given a weighting of 3 points, the orange sticker dot indicated rank ‘2’ (second most important) and was given 2 points and the red sticker dot indicated rank ‘3’ (third most important) and was given 1 point. They discussed the reasons for their choices. Each group came up with a list of features with the top three prioritised features marked with the stickers. The scores (based on the sticker dots) of each group reflected the combined experiences and opinions of the members of the group. Following this, the participants discussed considerations for implementing the navigator programmes and identified outcomes that were relevant in evaluating the ‘success’ of patient navigator programmes.
After the session, the scores for each feature of the navigator programme were summed across the breakout groups and presented to the other groups in the plenary session. During the final plenary discussions, the Chair (AT) asked a nominated speaker from each breakout group to summarise their discussion. Each group provided a summary about the important features of patient navigator programmes, impacts, outcomes and critical success factors for uptake and implementation into patient care.
All breakout and plenary discussions were audiotaped and transcribed verbatim. Transcripts were entered into HyperResearch (ResearchWare Inc, V.3.0) to enable coding and analysis of the data. CG reviewed the transcripts line-by-line and identified and coded concepts into themes reflecting the perspectives of patients at the time of the diagnosis of early CKD and their views on the usability and acceptability of a patient navigator programme for early CKD patients. The themes were discussed among the facilitators and investigators to ensure that they captured the full range and depth of the discussions.
Patient and public involvement
Patients were directly involved in the study. Authors NJS-R and VC are patients with CKD involved as co-investigators. CG (a caregiver) and NJS-R were involved with the facilitation of the workshop. As results emerged, we reviewed the results with patient co-investigators to obtain their feedback to ensure that we presented the findings in the most effective way beyond the research community to general populations. We also shared a summary of findings to the workshop participants and gave them an opportunity to review the findings.
Summary of workshop findings
We identified themes that reflected the experiences of patients with early CKD and their perspectives on the features and acceptability of a patient navigator programme. Four themes related to self-management, communication and access to care during early CKD: lost in the ambiguity of symptoms and management, battling roadblocks while accessing care, emotionally isolated and re-establishing lifestyle and forward planning. Five themes related to the acceptability of the patient navigator programme: trust and credibility, respecting patient choices and readiness, using accessible language, offering multiple ways to engage and communicate and confidentiality and privacy. Selected quotations for each theme are presented in table 2. The themes and respective subthemes are described below.
Themes related to self-management, communication and access to care
Lost in the ambiguity of symptoms and management
Not recognising the severity of CKD-related symptoms
Patients did not attribute the symptoms they experienced, such as fatigue, to CKD. Patients who experienced fatigue assumed ‘they probably needed more rest’ or were led to believe they had ‘imagined’ their health problems when they were told they were ‘a hypochondriac’. Others ‘felt fine’ and ‘didn’t particularly feel they had the disease’ and thus were not prompted to seek care. One patient mentioned that her clinician dismissed CKD-related symptoms as being anxiety-related.
Delay in diagnosis and treatment
Patients felt that some general practitioners (GPs) were not knowledgeable about CKD and commented that ‘a lot of times they don’t understand’ the symptoms and felt the management of the CKD was ‘beyond’ them. They believed that this caused a delay in their diagnosis and commencement of treatment. One patient reported that they had to ‘collapse before anything was really done about it’. Delays were also caused when patients had to go back and forth between specialists before agreement was made on a management plan.
Overwhelming shock and despair at prognosis
Patients unfamiliar with the disease (eg, those with no family history of CKD or who did not experience symptoms related to CKD) felt shocked, overwhelmed and unprepared for decision-making and treatment. One patient went ‘from a matter of not knowing what was happening’ with their body, to being ‘in emergency and then admitted into hospital and receiving treatment’ for a disease they were not aware of. On diagnosis, some patients assumed they were ‘going to die’.
Battling roadblocks while accessing care
Frustrated by inadequate information
Patients felt they received insufficient information from GPs and nephrologists. They felt uncertain about their prognosis. Patients sometimes ‘didn't fully understand’ their condition, ‘because nobody had actually given them information’ of what they had and ‘why’ they had it. Some resorted to educating themselves and used ‘Google’ to learn more about CKD or spoke with other patients—‘I needed to see another patient to understand what this disease was all about’.
Bewildered by fragmented services
Patients consulted different multidisciplinary clinicians, but felt that the services were disjointed, siloed, inconsistent and difficult to access. This made ‘life really difficult.’ Some patients felt that nephrologists did not provide them with adequate information and expressed exasperation about the perceived lack of communication among clinicians—‘get clinicians to communicate with each other or respect the need to re-consult back with each other every so often’. Some were unaware of services available and felt patients would not be referred to these additional services, such as dietitians, ‘unless the patient really asks’. One patient commented that they ‘have never seen a social worker…I didn't realise we had a designated renal social worker’.
Perplexed by medical terminology
Patients found it difficult to understand medical language and were unable to interpret their test results. They felt doctors were ‘so busy and it becomes extremely…technical, very jargonistic’. Patients needed the information provided in a ‘demedicalised and plain English’ language and format.
Dismissed, disrespected and disempowered in decision-making
Some patients found it difficult to engage with their clinicians in a constructive way that fostered a partnership approach to managing CKD. They felt disregarded as they were expected to just ‘sit there’ and ‘be told what to do’. Patients felt dismissed when doctors were ‘too busy’ to acknowledge and respond to their queries or concerns regarding the treatment.
Blindly trusting clinicians
Some patients ‘didn’t understand enough about the disease’ and thus relied on their nephrologists and nurses to make decisions. They trusted their doctors and did not want to participate in decisions about their treatment—‘I was totally guided by my nephrologist…he knew what he was talking about’.
Forced to cope alone
After being diagnosed with CKD, patients were often not referred to or offered psychosocial support. They felt that they were left to cope on their own—‘there was no information, no referral to a psychologist to help’ them through ‘the grieving process’. Being ‘so unwell’, patients did not have the ‘emotional energy’ to be their ‘own advocates’. They believed that ‘some sort of mentoring’ would have been ‘reassuring’ to help them ‘sleep better at night’.
Struggling to balance disease burden with family responsibilities
Patients emphasised that CKD affected their family, particularly parents with CKD who struggled to care for their children. They felt that assistance, such as having a ‘case worker’ would help to alleviate the burden on their family.
Re-establishing lifestyle and forward planning
Having to adjust to a restricted way of living
Patients were advised to make changes to their lifestyle after diagnosis such as restricting ‘potassium and phosphate and watching unhealthy foods’. Patients with polycystic kidney disease were asked to refrain from high impact activities that they enjoyed like ‘playing rugby’ and ‘horse riding’.
Struggling to pursue parenthood
Some patients who wanted to start a family were aware that CKD and its treatment increased the risk of infertility, pregnancy complications and congenital birth defects. They faced resistance from fertility specialists, and some women ‘changed doctors’ in an attempt to access better support and management of their pregnancy. One patient experienced a miscarriage after going through several cycles of in vitro fertilisation (IVF), and another mother had to undergo an early delivery due to an increased risk of a cardiovascular event. Patients lacked the confidence to ‘ask about specifics’ around their management of CKD and the way their medications (eg, appropriate dosage) were to be administered to have a safe pregnancy.
Acceptability of the patient navigator programme
The themes in this section focus on the acceptability of a patient navigator programme to potentially address some of the issues raised above.
Trust and credibility
To engage with the patient navigator programme, patients needed to be confident in the credibility of the navigator programme. They suggested that the programme should be promoted through trusted or familiar sources, for example, GPs, nephrologists and patient organisations. Some indicated they would prefer the navigator to have lived experience of CKD so they could ‘relate’ to them.
Respecting patient choices and readiness
Patients wanted the programme to be able to meet their individual needs and to have the choice and flexibility around participation in the patient navigator programme. Some felt it was acceptable for patients to be contacted by the navigator programme coordinators, while others felt it may be ‘too confronting’ and preferred to be informed about the programme before deciding to enrol.
Using accessible language
Patients felt that it was important to explain the programme using terms that were easily understood by patients with different levels of health literacy and education. They regarded the term ‘patient navigator’ to be potentially confusing and suggested alternatives including ‘helper’ or ‘support person’.
Offering multiple ways to engage and communicate
Patients suggested that different modes of communication with the navigator could increase engagement and uptake by diverse groups of patients. Some patients preferred to communicate online with the navigator while others preferred face-to-face or telephone contact. Some older patients stated that they ‘wouldn’t be online’.
Confidentiality and privacy
Protecting confidentiality and privacy during consultations with the navigator was important to patients. Some of the participants felt ‘there was no privacy at their clinic’. The discussions on sensitive or personal topics, for example, ‘insurance’ or ‘intimacy issues’, should be conducted in private settings.
Rankings of features of navigator programmes
The top five ranked features of patient navigator programmes were delivery of education (35 points), psychosocial support (35 points), lifestyle modification (16 points), communication and decision-making support (15) and facilitating care (referrals, communication and coordination) (14 points). Six new features were added: maintaining independence and living life, networking, translating medical information into plain language, advocacy and education for family and friends, need for patient navigators with ‘lived experience’ and caregiver support. Scores for each of the features are provided in table 3.
Patients and caregivers prioritised education, psychosocial support, communication and decision-making as the most important features of the patient navigator programme. An overall low level of awareness of CKD among patients and clinicians was believed to be a main reason for delays in the diagnosis and treatment. Following diagnosis, the immediate needs patients identified were education; to gain a better understanding of their disease and psychological support; to overcome the shock of diagnosis. Patients emphasised the need for adequate information, clarification with medical terminology and help with understanding the implications of their test results. They felt that patient navigators should have a role in providing or facilitating disease and treatment-related education and rated education as the top feature in the navigator programme.
The shock of being diagnosed with CKD along with fear of a severe and life-threatening prognosis was overwhelming and impaired their ability to cope and engage in self-management and healthcare. Without ready access to psychological or social support, some felt isolated and emotionally burdened. Patient navigator programmes could potentially identify and facilitate access to social support networks (family, friends and community groups) and psychological and social services (counsellors, psychologists and social workers). The use of online video conferencing platforms could also be considered and may be a more cost-effective way than in-person sessions.
Along with education and communication, patients emphasised the need for advocacy to support their choices and help them make informed decisions regarding their care. Patients reported that GPs lacked awareness about CKD and dismissed their symptoms or felt ridiculed and disempowered while asking questions and making decisions about their treatment. They wanted an advocate to help speak on their behalf when they needed clarity around their treatment, and a liaison to facilitate communication (eg, when patients were unable to explain their symptoms, felt unheard or disregarded by doctors, or when they had to manage conflicting advice from specialists). Patients who wanted information and support with regards to family planning (including pregnancy), needed assistance with coordinating services across multiple care settings (GPs, nephrologists and fertility specialists). The multifaceted and pervasive impact of CKD placed additional demands on the patients and families that navigators could assist with, for example, support for siblings of patients who felt neglected by their parents or managing ongoing stress among family members. Patients suggested that navigators could help to identify and coordinate services (eg, access to social workers to organise for practical assistance at home, or to liaise with the school or employers for extra support). They felt that the navigator programme must address these issues relating to lifestyle, communication, coordination and advocacy.
Overall, the needs of patients centred around education, communication, coordination and psychosocial support. Differences among patients were around life stages (eg, younger patients were more comfortable with online communication) and disease type. For example, patients with polycystic kidney disease were familiar with their disease and experienced less shock on diagnosis. They were influenced by family members’ experiences with the disease and were unfamiliar with the most up to date information on available treatment and services.
The role of a patient navigator may also focus on providing specific information to address vulnerable points in the patient’s disease trajectory. For example, assisting transition to dialysis by advocating for patient’s choice of dialysis modality; during transplantation by organising psychosocial support for caregivers; by liaising between nephrologists and other healthcare providers including fertility specialists and initiating discussions with female patients on fertility preservation and IVF.
While we generated diverse and relevant insights about self-management, access and priorities for patient navigator programmes for CKD, we recognise that some of the patients were receiving kidney replacement therapy at the time of the workshop. However, through prompting, participants were asked to reflect and focus on their diagnosis of CKD prior to the need for kidney replacement therapy. Patients who had commenced dialysis or received a kidney transplant had the benefit of hindsight and they could recognise various symptoms attributed to CKD only after they received treatment. We acknowledge that participants were all English-speaking, resided in Australia including some who were highly educated. Thus, there is some uncertainty about the transferability of the findings to other populations. This was conducted as a patient workshop with patients involved as co-investigators, therefore we did not collect detailed demographic and clinical characteristics and thus could not compare the data based on these characteristics including age, ethnicity, type of disease or treatment stage. Also, this was conducted as a single workshop with breakout group discussions, and we did not seek to achieve data saturation. However, we noted similar priorities and themes across the breakout groups. Future detailed work is suggested to understand the specific needs of patient populations including non-English speaking patients, Indigenous groups, and culturally and linguistically diverse groups to understand the unique barriers and challenges these groups face.
Based on the evidence for patients with chronic diseases other than CKD, patient navigator programmes can be seen to improve timely access to care and support self-management.11 Specifically patient navigator programmes have been shown to improve health literacy, build trust, reduce fear and improve patient–provider communication.12 In patients with cancer, trials have demonstrated that patient navigator programmes are associated with earlier initiation of treatment.27 One study conducted in patients with abnormal cancer screening results found that the patient navigator programme resulted in earlier diagnosis and treatment.27 Patient navigator programmes have also been shown to increase satisfaction with clinician-related interactions (eg, doctors availability, interpersonal skills, information, technical skills and psychosocial support) and to reduce hospitalisation in patients with head and neck cancers.28 Studies reveal positive feedback from patients with type 2 diabetes and healthcare providers when patient navigators were used for promoting lifestyle modifications.14 One study revealed that youths with type 1 diabetes found the navigator programme valuable as they transitioned from paediatric to adult care.13
However, patient navigator programmes for cancer and diabetes patients may not extrapolate to patients with early CKD due to the differences in the disease trajectory (progression to kidney failure requiring kidney replacement therapy) and treatments. Most of the information on patient navigation programmes relate to screening studies in cancer and a small number of studies pertain to kidney replacement treatment, including transplant education, accessing transplant waiting lists and living donation.18 29
There is little evidence for the effectiveness of navigator programmes among patients with early CKD. One trial compared the effect of a navigator programme for patients (with CKD stage 3 to 4) with enhanced personal health record to usual care. No difference was reported in clinical measures (estimated glomerular filtration rate, appropriate CKD-related laboratory measures and referrals to specialists) or hospitalisation.30 Nevertheless, the acceptance of the programme was high, although the study population comprised of patients with high literacy levels who were actively engaged in their own care. Another study in patients with advanced CKD close to the need for kidney replacement therapy reported that patient navigators increased access to psychological support.31 However, to date navigator programmes have had minimal involvement of patients in the design which may limit the uptake and effect on outcomes.15 30
Our workshop identified new and unique barriers and challenges that patients with early CKD encountered in accessing and navigating healthcare and described specific preferences for designing and implementing navigator programmes. Patients in our workshop identified some features that included support with maintaining their lifestyle, fulfilling their daily activities and responsibilities, facilitating networking and connecting with other patients for support and educating family and friends about CKD. Recommendations on various aspects of the programme included preferences in the way navigator programme could be promoted, implemented and the specific roles of a patient navigator. Patients identified preferred channels for promoting patient navigator programmes (eg, through trusted sources like their healthcare providers, promotional material including fliers, mobile applications and credible websites), options for recruitment (eg, choice to opt in) and mode of contact (through telephone, email, online or face-to-face). Patients indicated a preference for navigators that they could readily identify or establish rapport with (eg, navigators with lived experience of chronic conditions, or of similar age) and a flexible multimode delivery of navigator services (through applications, online and in person) with a focus on individualised tailored programmes. Privacy and confidentiality were highlighted as important. The role of a navigator included provision of information around logistics (eg, parking, childcare and transport), education (eg, information on their disease and treatment, discussions around fertility preservation and IVF) and coordination of care (eg, arranging appointments). Clarifying patient goals and assisting in making treatment decisions, providing social support (identifying social networks, facilitating access to psychologists and counsellors), encouraging and supporting appropriate medicine taking, assisting with lifestyle changes (eg, connecting with dietitian) were also deemed important. Box 1 provides a summary of recommendations for developing and implementing navigator programmes for patients with early CKD, derived from the workshop discussion.
Summary of recommendations to consider while developing patient navigator programmes for chronic kidney disease (CKD) patients
Implications for interventions of a patient navigator programme for patients with CKD
Promote patient navigator programmes through trusted and credible sources (eg, general practitioner or specialist).
Provide flexible options for patients to enrol in the programme.
Use a range of terms and language that can be easily understood, for example, alternative terms such as ‘helper’ rather than the term ‘navigator’.
Allow different modes of contact with the patient navigator (online, email, in-person meetings, telephone).
Protect confidentiality and privacy when communication with patient navigators.
Findings from this workshop will inform the design and implementation of a patient navigator programme for adults with CKD not yet requiring kidney replacement therapy. The programme will include features (eg, education, communication, coordination and advocacy) that have been identified as important to patients. In partnership with patients, we will calibrate the programme to best suit the target patient group. The findings will also be implemented in the development of the training programme and resources for navigators.
Patient navigator programmes should include features of high priority and relevance to patients including the delivery of education, identification of social support networks, advocacy of patient views and concerns, guidance in making lifestyle changes and assistance with communication and accessing services. In so doing the acceptability and uptake of patient navigator programme would be strengthened increasing the likelihood of improved treatment outcomes in patients with early CKD.
We acknowledge, with permission, all the patients and caregivers who contributed to the PAVE CKD workshop: Ian Russell Burns, Helen Coolican, Vanessa Cullen, Lino De Iulio, Julianne Ellis, Paul Grant, Charmaine Green, Luke Hackett, Kevin Hartley, Jill Hartley, Raymond Jeff, Helen Jeff, Luke McCauley, Mahasin Malek, Zubair Abdullah-Vettar, Lynne Ramnac, Carl Schmidt, Amanda Sluiter, James Stevens, Lachlan Stevens, Aaron Stevens, Susan Stevens, Glenda Von Wooten, Ian Williamson.
Twitter @scholes_nicki, @allisontong1
Collaborators The PAVE-CKD workshop investigators: Aaron Stevens, Amanda Sluiter, Carl Schmidt, Charmaine Green, Lino De Iulio, Glenda Van Wootten, Gopala Rangan, Helen Coolican, Helen Jeff, Ian Russell Burns, Ian Williamson, James Stevens, Jill Hartley, Julianne Ellis, Kevin Hartley, Lachlan Stevens, Luke Hackett, Luke Macauley, Lynne Ramanac, Mahasin Malek, Paul Grant, Raymond Jeff, Susan Stevens, Vanessa Cullen, Zubair Abdullah-Vettar
Contributors Author contribution: Research idea and study design: AT-P, GW, JC, PL-V; data acquisition: AB, AJ, AT, CG, NJS-R, RK, TG; data analysis/interpretation: CG, AT, PL-V. Each author (CG, AT, PL-V, AJ, TG, NJS-R, AB, GW, JC, TU, SR, VC, MH, RK, AT-P, KW, SS, TS, VWL, GKR, AM) contributed important intellectual content during the manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.
Funding The research has been funded by the Better Evidence and Translation in Chronic Kidney Disease Program Grant (App 1092957). The study funder did not have any role in the study design, data collection or analysis, writing of final manuscript or the decision to submit this manuscript for publication.
Competing interests None declared.
Patient consent for publication Not required.
Ethics approval The University of Sydney provided ethics approval for this project (Project no. 2019/160). Informed consent was obtained from participants before the workshop was convened.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement No data are available. All data relevant to the study are included in the article. No unpublished data are outside of the study team.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.